Who
Sunil Ratilal Karnawat
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Rezolute.
In numbers
- Trades disclosed
- 8
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Aug 2025
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $10K2,267 at $4.50 | filing |
| 2 Sep 2026filed 3 Sep 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $10K2,267 at $4.50 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $19K12,000 at $1.62 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $160100 at $1.60 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 18 Aug 2025filed 27 Aug 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 18 Aug 2025filed 27 Aug 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Sunil Ratilal Karnawat; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.